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Summary
BACKGROUND: In 2005, findings of the first “cost of
disorders of the brain in Europe” study of the European
Brain Council (EBC) showed that these costs cause a sub-
stantial economic burden to the Swiss society. In 2010 an
improved update with a broader range of disorders has been
analysed. This report shows the new findings for Switzer-
land and discusses changes.
METHODS: Data are derived from the EBC 2010 census
study that estimates 12-month prevalence of 12 groups of
disorders of the brain and calculates costs (direct health-
care costs, direct non-medical costs and indirect costs) by
combining top-down and bottom up cost approaches using
existing data.
RESULTS: The most frequent disorder was headache (2.3
million). Anxiety disorders were found in 1 million persons
and sleep disorders in 700,000 persons. Annual costs for
all assessed disorders total to 14.5 billion Euro correspond-
ing to about 1,900 EUR per inhabitant per year. Mood,
psychotic disorders and dementias (appr. 2 billion EUR
each) were most costly. Costs per person were highest
for neurological/neurosurgery-relevant disorders, e.g. neur-
omuscular disorders, brain tumour and multiple sclerosis
(38,000 to 24,000 EUR).
CONCLUSION: The estimates of the EBC 2010 study for
Switzerland provide a basis for health care planning. In-
crease in size and costs compared to 2005 are mostly due to
the inclusion of new disorders (e.g., sleep disorders), or the
re-definition of others (e.g., headache) and to an increase in
younger cohorts. We suggest coordinated research and pre-
ventive measures coordinated between governmental bod-
ies, private health-care and pharmaceutical companies.
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Introduction
According to the Review of Health Systems from the Or-
ganisation for economic co-operation and development
(OECD) a high performance and responsiveness has been
attributed to Switzerland due to a high availability of health
services, an unconstrained choice of health care providers,
a high patient satisfaction and one of the longest life ex-
pectancies of the world. However, this also has its price. In
2009 Switzerland spent 11.4% of its gross national product
on health which is more than 2% above the OECD average
[1]. In 2005, findings of the first “cost of disorders of
the brain in Europe” study of the European Brain Council
(EBC) [2] showed that the group of disorders of the brain
comprising mental, neurological and substance use disor-
ders contributed to about 16% of the health care costs in
Switzerland [3]. Nearly half of it refers to indirect costs
while 33% concern direct health care expenses and 19%
direct non-medical costs. When findings on total costs from
all 25 countries of the European Union plus Iceland, Nor-
way and Switzerland were cumulated, 386 billion EUR
were spent in 2005 for the assessed brain disorders. With
expenses of 9 billion EUR for its health system, Switzer-
land had spent most per capita [2]. The largest part of it was
spent for “mood disorders” (formerly called “affective dis-
orders”).
Although findings from the 2005 EBC study improved the
political recognition of the size and burden of disorders
of the brain on different European and national political
levels, incomplete age ranges and diagnostic scopes needed
an update of the data collection in 2010 including a broader
range of mental disorders and neurological conditions
across the whole life-span [4]. Whereas the 2005 studies
collected data on specific substance use disorders, psychot-
ic, mood and anxiety disorders as well as brain tumors, de-
mentia, epilepsy, headache, multiple sclerosis, Parkinson’s
disease, stroke and traumatic brain injury, the new stud-
ies additionally included data on child and adolescent dis-
orders, eating disorders, mental retardation, neuromuscular
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disorders, sleep disorders, somatoform disorders and two
additional personality disorders. These additional brain dis-
orders together with those already included in 2005 were
thought to have the highest impact on public health and
health economy in European countries.
After inclusion of data assessed in 2010, the total European
costs of disorders of the brain were estimated at about EUR
798 billion with the largest expenses for mood disorders
[5]. Disregarding the newly included disorders and exten-
sions of them in 2010 resulted in EUR 477 billion total
costs compared to EUR 386 billion in the 2005 EBC stud-
ies. The difference could be explained by simply inflat-
ing the cost and population size during the 5 years period.
While EUR 164 billion were allocated to extensions of the
2005 disorders (e.g. specific disregarded disorders were ad-
ded to the already reviewed groups as for example posttrau-
matic stress disorder to anxiety disorders) the new disor-
ders were estimated at EUR 157 billion total costs [5]. The
aim of the present paper is to provide the specific Swiss
data from the EBC 2010 study and to discuss them in re-
lation to those of other European countries and the former
study in Switzerland in 2005 [2].
Methods
The European study was commissioned by the EBC. The
EBC is a co-ordinating council formed by European organ-
isations in psychiatry, neurology, neurosurgery, basic neur-
oscience, and the European patient organisations in psychi-
atry and neurology as well as representatives of the brain-
related pharmaceutical industry. The council was designed
and managed by a steering committee that included pro-
fessors Olesen (Denmark), Wittchen (Germany) and Jöns-
son (Sweden). The major task of the EBC is to analyse the
size and burden of brain disorders in Europe and to make
recommendations for politics, research, teaching and pub-
lic awareness. For the “size and cost of disorders of the
brain in Europe-study”, the committee collaborated with
the health economists Gustavsson and Svensson as well as
members of expert panels related to the investigated disor-
ders1 (see also acknowledgement).
The study follows a societal perspective considering the
costs of all resources that were used or lost due to a disor-
der or disease. These costs included the direct health care
costs (i.e., prevention, diagnostic processes and treatment
for example in a hospital or by physicians visits), the dir-
ect non-medical costs (e.g., social services or caregiving,
informal care) and the indirect costs (e.g., through work
absence or early retirement). Pharmaceutical expenditures
were included in direct costs and estimated through use of
the ATC code allowing the identification of drug classes
used to treat disorders of the brain. Based on this system,
statistics on pharmaceutical sales are available from which
costs of drugs related to brain disorders can be derived. The
total costs were calculated by using epidemiological data
on the prevalence of a disorder under the consideration of
economic data stemming from cost of illness studies and
national or regional statistics.
Prevalence estimates were generated through expert re-
views of already existing findings from general population
studies or other sources. Similarly cost data were drawn
from literature reviews on already existing economic data.
The methodology of the study has been presented in detail
elsewhere [4, 5]. The specific steps of this approach that in-
cluded also reanalyses of epidemiological data will be de-
scribed in more detail below.
The current study extracts the relevant data from the EBC
2010 study [4, 5] and presents the data for Switzerland in
detailed fashion.
Prevalence data
The stepwise multi-method study approach of EBC 2010
[4] included first a literature search and review of eligible
existing epidemiological data from the general population
of the participating countries on the agreed diagnostic spec-
trum that was performed by expert panels1. Included stud-
ies were required to have used a population-based ap-
proach, explicit diagnostic information based on either re-
search criteria of ICD-10 (WHO, 1993) or diagnostic cri-
teria of DSM-III-R/DSM-IV (APA, 1994) and an assess-
ment with well-established diagnostic instruments. Preval-
ence estimates that were drawn from the literature ideally
referred to the preceding 12 months and were drawn from
studies that were conducted between 1980 and 2010. In ad-
dition to international reviews on prevalence findings as
for example from Tagliaferri et al. on brain injury epidemi-
ology in Europe [6], that are all available in [5], the fol-
lowing prevalence data from original Swiss studies were
included: dementia [7] and child and adolescent disorders
[8];
In case original country data from the literature were not
suitable the second step included re-analyses of data of
accessible epidemiological, nationwide, general population
studies as well as re-analyses of data from community stud-
ies from the participating countries to fill in gaps of estim-
ates of prevalence and other necessary information (e.g.,
on comorbidity). If country specific data still missed after
these procedures data from other countries were extrapol-
ated to the countries with missing data in a third step. Na-
tional expert surveys served as an independent validation
component of reviewed data or for use of additional “best
estimates” on prevalence data in cases data were not avail-
able by the first two steps.
For the aggregation of prevalence estimates of diagnostic
findings across all EU member states median percentages
and interquartile range (IQR) was most often reported. For
several diagnoses, the epidemiological panels derived “best
estimates” by judgement taking into account the median
and range of available estimates. This was the case
whenever the median appeared to be heavily biased by
methodological factors as for example in case of outlier
prevalence due to a limited sample from a certain age group
although there is evidence for varying age-specific pre-
valence estimates. In this instance, panel experts choose
the “best estimate” from a reference study. Furthermore,
disorder-specific variations between countries (e.g., for al-
cohol dependence) and the occurrence in specific age
groups were taken into account (e.g., for child and adoles-
cent disorders). The last one was considered by calibrating
the age specific prevalence reflecting the total population.
To avoid double counting specific disorders were adjusted
for comorbidity. This was for example done for personal-
Original article Swiss Med Wkly. 2013;143:w13751
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ity disorders which were assumed to be most likely already
counted with another mental disorder. Therefore personal-
ity disorders were excluded from overall prevalence estim-
ates. Data for Switzerland were attained by all four afore-
mentioned methods.
Cost of illness analyses
An approach consisting of “bottom-up”-cost-illness studies
assessing individual costs was chosen to identify country-
specific costs of disorders in the EBC 2010 study. It was
supplemented by the “top-down”-approach that used stat-
istical national or regional information of groups of disor-
ders for the identification of the specific costs of a certain
disorder [5]. Data were primarily drawn from literature
analyses of eligible studies conducted in the participating
countries. Included were studies that were published from
January 1st 2004 on and that investigated the specific dia-
gnoses among patients in the participating countries with
a robust methodology. The following original studies con-
tributed to Suisse cost data in the EBC 2010 study: brain tu-
mours [9], epilepsy [10], multiple sclerosis [11] and stroke
[12].
Data were entered in a “European cost of illness (COI)”-
model that estimated total costs by using the estimated pre-
valence of the disorders under consideration [5]. The model
also considers missing country-specific cost data by extra-
polations from other countries. Furthermore variations of
cost estimates related to the year of the assessment and the
specific currency on which the data were based were con-
sidered:
(1) All data on cost estimates were adjusted to 2010 values
considering country-specific inflation rates.
(2) All data on cost estimates were converted to real Euro
(EUR) with nominal exchange rates from the European
Central Bank.
(3) In case of unavailable eligible costs, estimate extrapol-
ation across countries by use of an adjusted median for in-
come, health care expenditure, and wage level differences
was performed.
(4) Prevalence estimates were then used to calculate pop-
ulation fractions with the specific brain disorders by mul-
tiplying the estimated prevalence ratios with the number
of people in each country in 2010 taking into account
disorder-specific age ranges and missing costs data for the
total population. The numbers of persons with each disor-
der (the population fractions) were then multiplied with the
estimated costs per patient in each country. Specific meth-
ods that have been used for missing data are described in
[5].
For the current study, relevant data for Switzerland were
again gained from all four sources. The currency utilised
for computation were EUR adjusted by the purchasing
power parity (PPP) that determines the relative value of
the specific currencies of each participating country for the
EBC 2010 database being in EUR, for the ease of compar-
ability across all involved countries.
Results
Estimated number of subjects with brain disorders in
Switzerland
Figure 1 shows the estimated numbers of affected subjects
by the combined categories of mental disorders and some
specific brain disorders.
Additionally data on the specific disorders within these
combined categories are shown in Appendix 1. The num-
bers of cases per 2010 are based on “best estimates” of
Figure 1
Estimated number of subjects with a specific disorders of the brain
in Switzerland in 2010 based on data from the 2011 European
Brain Council (EBC) study.
Figure 2
Total costs of specific disorders of the brain in Switzerland.
Figure 3
Total costs per affected subject in Switzerland.
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the prevalence of the disorders and it is important to note
again that for some specific disorders only cases of sub-
populations of the relevant age groups are reported. This
is true, for example, for child and adolescents disorders,
which only encompassed the age range of 0 to 17 years, or
dementia, which included only cases of 64 years and older.
Figure 1 reveals that headache with a clear majority of
tension-type headache accounted for nearly half of the
cases with brain disorders (see Appendix 1). Anxiety dis-
orders with more than one million cases and a majority of
specific phobias followed on in the second place. Interest-
ingly, the newly added category of sleep disorders, which
included insomnia for a major part (Appendix 1: 444 of the
683 cases), was the third most frequent disorder and was
nearly three times more prevalent than addiction. In con-
trast, neuromuscular disorders, brain tumors, and multiple
sclerosis were relatively rare.
Costs of brain disorders
Total costs
Based on the “European COI”-model the total costs of
brain disorders were specifically calculated for Switzerland
with the reported numbers of subjects as shown above and
the reviewed specific costs of disorders. In Switzerland the
total costs of all brain disorders under consideration were
estimated at 14 Billion and 574 Million EUR (nearly 20
Billion CHF in 2010). Figure 2 displays the total costs by
groups of disorders and some specific disorders (orange
columns). In addition, the numbers of subjects are repres-
ented by grey columns.
With more than 2 Billion Euro expenses in 2010, mood
disorders were the most costly group of brain disorders
followed by psychotic disorders. Given the relatively low
number of cases with psychosis as compared to those with
mood disorders, the high total cost of psychosis was prob-
ably attributable to the high functional impairment related
to this disorder that even doubles the high cost of inpatient
treatment. Regarding headache, the 752 Million Euros
spent for this condition lie in the mid range of costs despite
its high prevalence. In contrast, several disorders with low
prevalence caused high total costs. One of them was mental
retardation that cost nearly one billion Euros. Another ex-
ample was stroke, which lies in the mid range of prevalence
estimates, but caused costs comparable to those of sleep
disorders with a much higher prevalence.
Figure 4
Total costs per discipline (million €PPP, 2010).
Types of costs
The societal perspective as considered here distinguished
between direct health care costs that include all medical
costs, direct non-medical costs, including for example costs
for social services, and indirect costs encompassing periods
of inability to work and early retirement. Table 1 shows
how these costs were distributed with respect to the disor-
ders.
Direct health care costs were with 5 Billion and 726 Mil-
lion EUR the highest burden of brain disorder as shown in
the last row of table 1. However nearly the same amount
were lost earnings for brain disorders due to inability to
work or early retirement, whereas direct non-medical
healthcare costs added up to an amount that was lower:
3.2 Billion EUR. It is noteworthy that anxiety disorders re-
quired most direct healthcare resources in terms of cost. On
the other hand, dementia accounted for nearly half of the
total of direct-non medical costs. Moreover, indirect costs
were particularly high for mood and for psychotic disor-
ders with one third of all indirect costs being attributable to
these two disorders. Similarly, headache, personality disor-
ders and to a lower degree neuromuscular disorders mostly
caused indirect costs, whereas stroke for example entailed
high direct health care costs and only moderate non-med-
ical and indirect costs. Given the restricted age range, no
indirect costs were estimated for dementia and child or ad-
olescent disorders. The other missing values in table 1 were
due to lack of information from cost data reviews.
Costs per subject
The estimation of costs per subject is also important for the
allocation of financial resources although the validity of the
data of the ECB 2010 was limited due to the possibility of
double counting. Even though this bias has been minimized
by considering the excess costs of each disorder, this limit-
ation should be acknowledged when costs per subjects are
reported. In total, subjects with brain disorders or diseases
were estimated to cost 2.624 EUR in 2010. Figure 3 com-
pares the cost per subject by groups of disorders or by spe-
cific disorders.
In contrast to the total costs, the costs per case were particu-
larly high among relatively rare brain disorders. Neuromus-
cular disorders caused the highest costs per case partially
due to their severe consequences, whereas ‘headache’ the
most common brain disorder, or anxiety disorder, the most
prevalent mental disorders, caused relatively low costs per
case. Among mental disorders, psychotic- and personality
disorders were most expensive when evaluated per subject.
Again, all data were adjusted for disorder-specific comor-
bidity patterns.
Costs per subjects by specific types of costs
Table 2 shows that most direct health care costs per subject
were spent for the treatment of brain tumours followed
by neuromuscular disorders. As shown in Appendix 1,
Guillan-Barré syndrome (GBS) in particular caused very
high direct health care costs per subject within the neur-
omuscular disorder category. In contrast, direct health care
costs per subject of dementia were moderate; but the direct
non-medical costs per subject were higher than those for
all other disorders. Both neuromuscular disorders and
Original article Swiss Med Wkly. 2013;143:w13751
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psychotic disorders caused particularly high indirect costs
per subject. With respect to personality disorders, the relat-
ively high costs per case as compared to the other mental
disorders were essentially due to borderline personality dis-
order (Appendix 1). The costs per subject of the other men-
tal disorders were in the moderate to lower range.
Total costs per discipline
We also aimed to divide the total costs by discipline. Psy-
chiatry includes the following disorders: psychotic, person-
ality, child/adolescent, mood, anxiety, somatoform and eat-
ing disorders were assigned to Psychiatry. Neurology alone
was decided to include: neuromuscular disorders, multiple
sclerosis, headache. A mixed neurology/neurosurgery cat-
egory was defined to consist of brain tumours, Parkin-
son’s disease, traumatic brain injury, stroke and epilepsy.
A mixed neurology/psychiatry category included demen-
tia, mental retardation, addiction (alcohol use disorders and
opioid dependence), and sleep disorders. Note that clinic-
al psychology or neuropsychology contribute to all these
medical disciplines to a greater or lesser extent.
Figure 4 shows that 6.9 billion EUR total costs were al-
located to Psychiatric care. If neurological costs were com-
bined with psychiatric and neurosurgery costs they sum-
marize to 7.7 billion EUR with 1.087 Billion EUR alloc-
ated to core neurological diseases.
Discussion
The new data on the size and burden of brain diseases or
disorders from the EBC 2010 studies have provided an up-
date of the 2005 assessment of disorders of the brain in the
European Union, Iceland, Norway and Switzerland. The in-
clusion of a broader set of diagnoses than in the first study
in 2005 has led to a two times higher estimate of the costs
of brain disorders in 2010. With respect to Switzerland, the
total cost of nearly 9 Billion EUR in 2005 rose to 14.5 Bil-
lion EUR in 2010, which is a slightly smaller increase com-
pared to that of other countries. The specific findings and
limitations as well as the implications will be discussed in
the following sections.
The frequency of brain disorders
Between 2005 and 2010 the estimated number of diagnoses
of disorders of the brain in Switzerland increased remark-
ably [3]. A significant part of the increase resulted from the
inclusion of the tension type headache that had not been as-
sessed in 2005. Together with the two other new types of
headache it accounted for 1.5 Million cases. Another mil-
lion cases were attributable to disorders that were newly
included in the 2010 assessment. These new disorders in-
cluded sleep disorders, somatoform disorders and child and
adolescent disorders. However, compared to the assess-
ment in 2005 there was also an increase within the anxiety
disorders category (about 300’000 more cases), mood dis-
orders and addiction (each about 100’000 subjects more),
and psychotic disorders (40 000 more cases). A part of
some of the increase within categories relied on the exten-
sion in the EBC 2010 coverage of disorders, e.g., post-trau-
matic stress disorder was recently included in the anxiety
disorders category and opioid dependence has been only
recently added [4]. Therefore the real increase of affected
individuals was much lower than suggested by the over-
all difference of affected subjects between the two assess-
ments which is in line with findings from other particip-
ating EBC countries that partially found few differences
between the two assessments when regarding the former
disorder categories [4].
With respect to the relatively small remaining increase of
affected individuals (about 700.000 persons) in Switzer-
land that might be not attributable to the extensions the spe-
cific Swiss data from more recent studies, new country spe-
Table 1: Total costs of direct healthcare-, non-medical- and indirect costs.
Costs (million €PPP, 2010)
Collapsed groups of brain disorders/
specific disorders
Total costs Direct healthcare costs Direct non-medical costs Indirect costs
Addiction 1.234 490 287 457
Anxiety disorders 1.500 987 2 511
Brain tumour 103 68 * 35
Child/Adolescent disorders 431 55 376 n.a.
Dementia 1.826 355 1.471 n.a.
Eating disorders 17 13 1 3
Epilepsy 241 148 25 68
Headache 752 182 0 570
Mental retardation 912 628 284 *
Mood disorders 2.144 557 307 1.280
Multiple sclerosis 187 54 71 62
Neuromuscular disorders 148 39 29 80
Parkinson’s disease 232 109 96 27
Personality disorders 515 72 54 389
Psychotic disorders 1.849 622 * 1.227
Sleep disorders 704 419 0 285
Somatoform disorder 417 205 * 212
Stroke 734 510 172 52
Traumatic brain injury 628 213 66 349
Total 14.574 5.726 3.241 5.607
* = unavailable; n.a. = not applicable due to restricted age range
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cific reports or updated “best estimates” for Switzerland
that regarded for example the country-specific increase of
older age cohorts may have been responsible. Furthermore
an overall population increase has been notified from the
Switzerland and other European countries between 2005
and 2010,
On the other hand there is an ongoing debate on other
causes. In clinical studies it could be attributable to lower
barriers for individuals with mental disorders to seek pro-
fessional help. Alternatively, increased proneness of sub-
jects to report psychiatric symptoms or a real cohort effect
as for example an increase of cases in younger cohorts as
for example with respect to substance use disorders could
explain elevated prevalence estimates of mental disorders
in more recent studies [13]. In contrast the increasing pre-
valence of dementia is expected given the aging of the pop-
ulation in developed countries [14] and the 25% risk for de-
mentia of all causes in individuals aged 90 years and older
[15].
Costs of brain disorders
The costs of disorders of the brain raised from EUR 8.9
Billion in 2005 to EUR 14.5 Billion in 2010. These higher
costs were mostly attributable to the increase of subjects
and diagnoses, respectively, included into the 2010 report.
Similarly to the 2005 assessment, the largest part of the
total costs in Switzerland was allocated to care for mood
disorders [3]. Dementia costs increased from 320 Million
by a factor of 5.5 to 1.8 Billion. Swiss data from 2007 [16]
reported even higher costs of 3.5 billion (without indirect
cost), but these differences may be explained by different
calculations for institutional care costs. For substance use
disorders the overall costs remained unchanged despite an
increase of the prevalence of these disorders since 2005.
However, there were also some significant reductions of
costs of some disorders. For instance, epilepsy costs de-
creased from 370 million to 240 million, while Multiple
sclerosis costs decreased from 290 to 190 million. These
developments are difficult to explain. Compared with the
2005 data, direct non-medical costs decreased for both epi-
lepsy and multiple sclerosis. Moreover, there was a strong
decrease of indirect costs for epilepsy, raising the possib-
ility that improved treatment options and altered patterns
of care were largely responsible for the overall decrease in
cost.
In the neurology/neurosurgery area the total costs for stroke
increased by a factor of 2.5 fold to 730 Million EUR. This
increase is in line with high costs reported in the United
Kingdom for this category [17, 18]. It might reflect in-
creased use of new treatment options such as thrombolyt-
ic therapy and more extensive neurorehabilitation which,
however, should result in a stronger decrease in indirect
cost than has been reported so far. But even more, the new
data on traumatic brain injury also revealed a steep increase
from 67 to 628 Million EUR. In 2005 cost data for this cat-
egory lacked direct non-medical costs as well as indirect
costs and were estimated to a three times lower amount for
direct health care costs [3]. This latter difference may be
due to different uses in disease registration; registration for
TBI or subarachnoid haemorrhage is currently only in the
process of its nationwide establishment [18, 19].
When comparing the Swiss total costs to the European part-
ners of the EBC study as has been done by Gustavsson
et al. [5], Switzerland lies between Portugal (13.130 €PPP
million) and Austria (15.996 €PPP million) which corres-
ponds to much lower expenditures as compared to the lead-
ing partner Germany with 152,719 €PPP million. However,
more meaningful to compare but also limited to model es-
timations and different wage levels are the costs per capita
which show that Switzerland is in 2010 in the 7th position
right behind Germany among the 30 partners with about
1.900 EUR per capita (European mean, 1.550 EUR).
Table 2: Direct healthcare, non-medical and indirect costs annually per subject.
Costs per subjects (€PPP, 2010)
Collapsed groups of brain disorders/
specific disorders
Total costs Direct healthcare costs Direct non-medical costs Indirect costs
Addiction 5.222 2.073 1.216 1.933
Anxiety disorders 1.422 936 2 485
Brain tumour 29.334 19.295 * 10.039
Child/Adolescent disorders 4.790 609 4.181 n.a.
Dementia 14.702 2.858 11.844 n.a.
Eating disorders 752 559 62 131
Epilepsy 6.308 3.879 645 1.785
Headache 319 77 0 242
Mental retardation 14.236 9.808 4.428 *
Mood disorders 4.224 1.098 605 2.521
Multiple sclerosis 24.422 7.073 9.258 8.090
Neuromuscular disorders 37.769 9.913 7.348 20.508
Parkinson’s disease 13.161 6.172 5.446 1.543
Personality disorders 7.752 1.082 818 5.852
Psychotic disorders 24.314 8.174 * 16.140
Sleep disorders 1.032 614 * 418
Somatoform disorder 1.345 662 * 683
Stroke 10.303 7.161 2.417 725
Traumatic brain injury 11.061 3.745 1.164 6.152
Total 2.624 988 559 1.076
* = unavailable; n.a. = not applicable due to restricted age range
Original article Swiss Med Wkly. 2013;143:w13751
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Limitations
Although the present paper was based on information from
a variety of Swiss or international studies as well as the
judgment of experts in the field, the results need to be con-
sidered in the context of several limitations:
First, data on prevalence estimates from epidemiological
studies were not available for all disorders in all particip-
ating countries including Switzerland. This limitation was
minimized by using different methods to include other data
on prevalence e.g., from national reports or by assuming a
European median prevalence which was used for extrapol-
ation of data across countries. Moreover there were only
few complete original cost-data available for Switzerland
which made it necessary to use data from other countries
for cost extrapolation after adaptation to the income, ex-
penditure or wage level of Switzerland.
Second, most cost data were based on clinical samples that
were not representative for the overall patient population of
disorders under consideration. The risk of an overestima-
tion of costs by using mostly treated subjects was reduced
by the introduction of severity categories.
Third, double counting of subjects affected by more than
one disorder could have entailed an overestimation of ag-
gregated costs although cost estimates were based on ex-
cess costs of the specific disorders.
Fourth, the estimates of the size and costs of disorders of
the brain did not include the whole range of disorders of the
brain which resulted in cost estimates that were rather con-
servative. For example, nicotine dependence was not in-
cluded. In addition, not all costs for specific disorders were
available.
Conclusions and implications
Despite the above-mentioned limitations, this update to the
EBC studies currently presents the best possible estimate of
the size and burden of disorders of the brain in Switzerland.
The total costs of these disorders that were assessed in 2010
correspond to nearly 10% of the costs of the Suisse health
system if only the direct health care costs are taken. This
significantly exceeds the estimations of the 2005 EBC data
for Switzerland [3] and, thus, highlights the clinical and so-
ciety burden of disorders of the brain which must be taken
into account by decision makers in health services and fin-
ance departments. Only cardiovascular diseases, which oc-
cupy the second position in terms of cost, cause a compar-
able burden of disease [20].
Very few data exist on the other disorder groups in Switzer-
land for the last 5 years besides the already in [3] men-
tioned obesity, asthma and severe sepsis. Particular cost es-
timations were recently published on Swiss data on acute
coronary syndrome [21], psoriasis [22], low back pain [21]
and major surgical procedures [23]. Again, in accordance
with WHO data on the burden of diseases in high and
middle income countries, the costs of disorders of the brain
far outweigh the costs of other disease-groups like cancer
and metabolic diseases.
The enormous size and burden of disorders of the brain in
Switzerland emphasizes the major need of increased efforts
in research fields of psychiatry, neurology, and neurosur-
gery as well as of neuropsychology and epidemiology. This
should be considered as a priority for the national health
and research budget. Switzerland, like other highly deve-
loped countries in the world, should focus its research on
causes and risks of diseases with the ultimate goal of im-
proving prevention. If national policy has recently rein-
forced the role of primary care medicine, this effort has to
be balanced out with appropriate means to also strengthen
the role of medical and psychological specialities. Al-
though some of the most prevalent disorders of the brain,
such as mood or sleep disorders, headache and dementia
also play a significant role in primary care, the progress in
treating these and more cost-intensive conditions will de-
pend on scientific progress in the concerned specialities.
Structurally, being one of the smaller European countries,
Switzerland has the chance to develop new models of in-
tegrated research cooperation that include governmental
bodies, private health-care and pharmaceutical companies.
This would be a promising approach, especially in the areas
of the highly complex disorders of the brain. Finally, as
already outlined in [3] with respect to the 2005 data, the
Swiss society needs a permanent effort to monitor and ana-
lyse the size and burden of these disorders through continu-
ous studies in order to improve the allocation of health ser-
vices in the future.
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Appendix 1
Appendix 1
Cost per subject (in €PPP per 2010) Total cost (in million €PPP per 2010)Disorders/diseases Number of
subjects (in
thousands)
Direct
healthcare
cost
Direct non-
medical cost
Indirect cost Total cost Direct
healthcare
cost
Direct non-
medical cost
Indirect cost Total cost
Addiction 236 2.073 1.216 1.933 5.222 490 287 457 1.234
– Alcohol 221 1.904 1.285 2.055 5.244 422 284 455 1.161
– Opioids 15 4.582 187 116 4.886 68 3 2 73
Anxiety disorders 1.054 936 2 485 1.422 987 2 511 1.499
– Agoraphobia 134 471 0 911 1.382 63 0 122 185
– GAD 135 1.378 0 273 1.652 185 0 37 222
– OCD 44 775 0 270 1.045 34 0 12 46
– Panic disorder 120 1.179 0 792 1.971 142 0 95 237
– PTSD 117 1.488 18 0 1.506 174 2 0 177
– Social phobia 154 1.018 0 570 1.588 157 0 88 244
– Specific phobia 350 659 0 449 1.108 231 0 157 388
Brain tumour 4 19.295 0 10.039 29.334 68 0 35 103
Child/Adolescent disorders 90 609 4.181 0 4.790 55 376 0 430
– ADHD 50 656 393 0 1.048 32 19 0 52
– Autism 8 1.799 35.168 0 36.967 15 291 0 306
– Conduct Disorder 32 228 2.026 0 2.255 7 65 0 72
Dementia 124 2.858 11.844 0 14.702 355 1.471 0 1.826
Eating disorders 23 559 62 131 752 12,8 1,4 3,0 17,2
– Anorexia 13 992 104 223 1.319 12,6 1,3 2,8 16,7
– Bulimia 10 22 10 17 49 0,2 0,1 0,2 0,5
Epilepsy 38 3.879 645 1.785 6.308 148 25 68 241
Headache 2.360 77 0 242 319 182 0 570 752
– Migraine 767 114 0 324 438 87 0 248 336
– Medicine overuse 107 420 0 2.396 2.817 45 0 257 302
– Other headaches 166 45 0 28 73 7 0 5 12
– Tension type 1.319 32 0 45 77 42 0 60 102
Mental retardation 64 9.808 4.428 0 14.236 628 284 0 912
Mood disorders 508 1.098 605 2.521 4.224 557 307 1.280 2.144
– Bipolar disorder 46 870 733 7.125 8.727 40 34 328 402
– Major depression 462 1.121 593 2.062 3.775 517 274 952 1.743
Multiple sclerosis 8 7.073 9.258 8.090 24.422 54 71 62 187
Neuromuscular disorders 3,9 9.913 7.348 20.508 37.769 38,6 28,6 79,9 147,1
– ALS 0,8 15.611 15.056 5.537 36.204 12,5 12,1 4,4 29,1
– CIDP 0,2 21.538 3.578 4.461 29.577 4,7 0,8 1,0 6,4
– GBS 0,1 71.863 0 2.789 74.651 7,2 0,0 0,3 7,5
– MMN 0,0 21.538 3.578 4.461 29.577 0,8 0,1 0,2 1,2
– Muscular dystrophies 2,0 1.833 7.226 35.831 44.890 3,7 14,7 72,8 91,2
– Myasthenia gravis 0,6 12.672 1.014 1.319 15.006 7,9 0,6 0,8 9,3
– PDN 0,1 21.538 3.578 4.461 29.577 1,7 0,3 0,3 2,3
Parkinson's disease 18 6.172 5.446 1.543 13.161 109 96 27 232
Personality disorders 66 1.082 818 5.852 7.752 72 54 389 515
– Antisocial 31 784 0 3.249 4.033 24 0 100 124
– Borderline 36 1.337 1.519 8.083 10.939 48 54 289 392
Psychotic disorders 76 8.174 0 16.140 24.314 622 0 1.227 1.849
Sleep disorders 683 614 0 418 1.032 419 0 285 705
– Hypersomnia 48 1.142 0 549 1.691 54 0 26 80
– Insomnia 444 213 0 0 213 95 0 0 95
– Narcolepsy 1 2.577 0 4.541 7.117 4 0 6 10
– Sleep apnea 190 1.404 0 1.331 2.734 267 0 253 520
Somatoform disorder 311 662 0 683 1.345 205 0 212 418
Stroke 71 7.161 2.417 725 10.303 510 172 52 733
Traumatic brain injury 57 3.745 1.164 6.152 11.061 213 66 349 628
Total 5.793 988 559 1.076 2.624 5.724 3.241 6.234 15.199
1 = Alcohol use disorders and opioid dependence
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Figures (large format)
Figure 1
Estimated number of subjects with a specific disorders of the brain in Switzerland in 2010 based on data from the 2011 European Brain Council
(EBC) study.
Original article Swiss Med Wkly. 2013;143:w13751
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 10 of 12
Figure 2
Total costs of specific disorders of the brain in Switzerland.
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Figure 3
Total costs per affected subject in Switzerland.
Figure 4
Total costs per discipline (million €PPP, 2010).
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